Hypertension Management Algorithm

Hypertension affects nearly half of all adults and is the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease. The 2017 ACC/AHA guidelines lowered the diagnostic threshold to 130/80 mmHg, classifying more patients for earlier intervention. This algorithm guides you through evidence-based decision-making from initial BP assessment through drug selection and follow-up, with educational explanations at every step.

The 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults is the most comprehensive evidence-based guideline for hypertension management in the United States. It introduced new BP categories, emphasized 10-year ASCVD risk for treatment decisions, and recommended a target BP of <130/80 mmHg for most adults. The guidelines were based on systematic reviews of randomized controlled trials including SPRINT, ALLHAT, and ONTARGET.

While these guidelines are evidence-based, they have recognized limitations:

• The algorithm simplifies complex clinical scenarios. Real patients may have multiple comorbidities requiring individualized therapy beyond what any algorithm can capture.
• The ASCVD risk calculator has known limitations in certain populations, including younger adults, women, and some ethnic groups where risk may be over- or underestimated.
• Drug selection recommendations are generalized. Individual factors such as drug interactions, patient preferences, cost, and access must be considered in practice.
• The 130/80 mmHg target remains debated. Some guidelines (e.g., ESC/ESH 2018) use different thresholds for different age groups and comorbidities.